Table 2.

Means and 6-month changes in immunological, neuroendocrine, and clinical health outcome variables by HIV-1 serostatus and treatment assignmenta

Outcome measureaTreatment PvaluebHIV-1+ subject group
InterventionControl
T1T2T3Δ(T3-T1)T1T2T3Δ(T3-T1)
Immunological:
 CD4 cell count0.041351.0 (42.9)c 328.0 (47.1)329.4 (59.8)−21.6 (39.3)432.6 (85.6)349.7 (34.7)372.0 (51.5)−60.6 (55.5)
 Total T lymphocyte count0.0301,042.0 (60.9)997.0 (74.0)1,075.4 (99.2)33.4 (72.8)1,115.9 (132.7)958.0 (100.8)1,029.3 (64.1)−86.6 (86.4)
 Total lymphocyte count0.0291,298.2 (69.8)1,268.3 (78.7)1,346.7 (103.8)48.5 (73.5)1,338.9 (142.6)1,204.3 (100.4)1,237.5 (76.4)−101.4 (92.4)
 CD8 cell count0.344668.5 (45.7)657.7 (50.4)663.3 (64.7)30.1 (59.6)662.7 (120.1)609.1 (79.7)610.7 (55.0)−52.0 (77.1)
 CD4/CD8 ratiod 0.7860.47 (0.61)0.44 (0.49)0.41 (0.49)−0.05 (0.21)0.63 (0.76)0.67 (0.54)0.60 (0.62)−0.03 (0.36)
Neuroendocrine:
Plasma cortisol level (μg/dl)0.001410.4 (0.7)11.0 (1.1)9.3 (0.9)−1.2 (1.0)8.5 (1.9)11.6 (0.9)12.1 (1.8)3.6 (3.1)
Clinical:
No. of health care visits prior 6 mo0.023e 1.28 (0.33)2.52 (0.53)3.04 (0.54)1.76 (0.58)3.43 (0.92)2.79 (1.67)6.36 (2.70)2.93 (2.14)
HIV-1 subject group
InterventionControl
T1T2T3Δ(T3-T1)T1T2T3Δ(T3-T1)
820.6 (35.4)866.0 (44.2)932.7 (79.3)112.1 (66.9)799.6 (66.7)761.5 (47.2)711.9 (36.2)−87.7 (58.9)
1,303.6 (60.0)1,239.0 (70.0)1,452.6 (106.7)149.0 (75.1)1,251.7 (79.2)1,219.2 (83.8)1,145.0 (58.3)−106.7 (86.2)
1,690.5 (74.1)1,632.8 (66.7)1,852.5 (136.3)162.0 (98.3)1,608.8 (101.9)1,568.1 (101.2)1,485.1 (81.0)−123.7 (114.7)
515.7 (44.1)460.6 (35.5)575.7 (57.2)60.0 (57.1)471.0 (38.9)432.1 (42.1)441.3 (39.1)−29.7 (34.7)
1.70 (0.83)1.85 (1.58)1.87 (0.94)0.17 (0.84)1.69 (0.82)1.85 (0.80)1.49 (0.96)−0.001 (0.43)
11.9 (1.2)9.6 (0.9)10.0 (1.2)−1.9 (1.3)10.3 (1.2)11.8 (0.7)12.3 (1.6)2.0 (1.6)
0.36 (0.15)1.27 (0.86)0.86 (0.23)0.50 (0.35)0.85 (0.30)1.0 (0.41)1.85 (0.60)1.0 (0.54)
  • a This table is based on the sample with measures at all time points (n immune[n I] = 87, n cortisol[n C] = 65, n health visits [n H] = 74). For T1-T2,n I = 105, n C = 90, andn H = 90; for T1-T3, n I = 89, n C = 77, and n H = 81.

  • b This is the P value for the T1-T3 contrast.

  • c Values given in parentheses are standard errors unless otherwise indicated.

  • d Medians are used as a measure of central tendency for CD4/CD8 ratio due to the presence of outliers. The number in parentheses is the interquartile range.

  • e The planned RANOVA for health care was significant (P = 0.023), as its P value shows; the post hoc T1-T3 contrast P was not significant.